Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 133, Issue -, Pages 124-130Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2017.08.018
Keywords
Transforming growth factor beta (TGF-beta); Fibrosis; Diabetic cardiomyopathy (DCM); MicroRNAs (miRNAs); Long non-coding RNAs (lncRNAs)
Categories
Funding
- National Natural Science Foundation of China [81472149]
- Zhejiang Provincial Natural Science Foundation of China [LY16H270003]
- Fundamental Research Funds for the Central Universities [2016QNA7003]
Ask authors/readers for more resources
Cardiovascular diseases account for the major cause of morbidity and mortality among individuals with diabetes. The diabetic cardiomyopathy (DCM) is a type of diabetic cardiovascular disease, which further directs to the heart failure. The researchers found that diabetes induced cardiac fibrosis plays a vital role in several of the pathological changes that associated with DCM, causing left ventricular hypertrophy (LVH), diastolic dysfunction and systolic dysfunction. However, the mechanisms involved in the pathogenesis of DCM are still elusive. Many studies have demonstrated that the transforming growth factor beta (TGF-beta) is one of the molecular mediators implicated in the progression of fibrogenesis. In diabetes, hyperglycemia causes the expression changes of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), TGF-beta genes, TGF-beta proteins and their receptors. Activated TGF-beta further leads to cardiac fibrosis, which in turn inducing DCM through the SMAD-dependent and independent pathways. Here, we reviewed the the molecular pathways that activate TGF-beta then leading to cardiac fibrosis, which induced the pathological changes of DCM. Illustrating the pathways of TGF-beta would propose an efficient way for the management of diabetic cardiomyopathy (see Fig. 1). (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available